- Home
- HNVR vs STRO Comparison
HNVR vs STRO Comparison
Compare HNVR & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNVR
- STRO
- Stock Information
- Founded
- HNVR 2008
- STRO 2003
- Country
- HNVR United States
- STRO United States
- Employees
- HNVR N/A
- STRO N/A
- Industry
- HNVR Commercial Banks
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HNVR Finance
- STRO Health Care
- Exchange
- HNVR Nasdaq
- STRO Nasdaq
- Market Cap
- HNVR 129.7M
- STRO 147.6M
- IPO Year
- HNVR 2022
- STRO 2018
- Fundamental
- Price
- HNVR $24.25
- STRO $1.77
- Analyst Decision
- HNVR Buy
- STRO Strong Buy
- Analyst Count
- HNVR 1
- STRO 7
- Target Price
- HNVR $22.00
- STRO $12.14
- AVG Volume (30 Days)
- HNVR 12.8K
- STRO 950.7K
- Earning Date
- HNVR 04-16-2025
- STRO 03-24-2025
- Dividend Yield
- HNVR 1.65%
- STRO N/A
- EPS Growth
- HNVR N/A
- STRO N/A
- EPS
- HNVR 1.66
- STRO N/A
- Revenue
- HNVR $63,491,000.00
- STRO $160,955,000.00
- Revenue This Year
- HNVR N/A
- STRO N/A
- Revenue Next Year
- HNVR $16.61
- STRO N/A
- P/E Ratio
- HNVR $14.61
- STRO N/A
- Revenue Growth
- HNVR 6.76
- STRO 230.90
- 52 Week Low
- HNVR $13.62
- STRO $1.51
- 52 Week High
- HNVR $27.14
- STRO $6.13
- Technical
- Relative Strength Index (RSI)
- HNVR 37.30
- STRO 42.89
- Support Level
- HNVR $25.75
- STRO $1.76
- Resistance Level
- HNVR $25.93
- STRO $1.95
- Average True Range (ATR)
- HNVR 0.57
- STRO 0.13
- MACD
- HNVR -0.28
- STRO 0.00
- Stochastic Oscillator
- HNVR 8.62
- STRO 41.94
About HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.